Led · Series A · Mar 2022

Apollo Neuro builds a scientifically validated wearable that delivers gentle, silent vibrations to the wrist or ankle to train the nervous system to recover from stress, improving sleep, relaxation, focus, and recovery. The device pairs with a mobile app, is sold for a one‑time price of $349, and is available in the United States, Canada, Europe, and Australia/New Zealand. Preliminary results from an ongoing sleep study launched in 2021 (more than 500 participants) showed average improvements including a 19% increase in deep sleep, 14% increase in REM sleep, 5% lower resting heart rate, and an 11% average increase in heart rate variability. Across broader research cited by the company, users experienced on average 40% less stress and anxiety, 30 more minutes of sleep, 50% more energy, and up to 25% more focus. The product was developed by neuroscientists and physicians and is positioned as a non‑invasive, side‑effect‑free tool for adults and children, with use cases ranging from expectant mothers to veterans and first responders. The company says it will use new funding to accelerate consumer health advancements and expand reach to new global users.

Participated · Series A · Sep 2021

Delix Therapeutics develops small‑molecule psychoplastogens that rapidly induce structural and functional neural changes in targeted brain areas. Its compounds are inspired by psychedelic compounds but are engineered to preserve efficacy while avoiding hallucinogenic properties and other safety liabilities. The company is advancing multiple candidates through preclinical and clinical development with the goal of bringing FDA‑approved, take‑home medicines to patients. Delix intends to use new funds to grow its drug development program, expand its pipeline and platform, hire additional team members, and pursue strategic opportunities in 2022. The company is led by CEO Mark Rus and is based in Boston, MA. Financially, Delix recently completed a convertible note financing and secured a strategic credit facility to support its programs alongside a prior $70M Series A in September 2021. Delix Therapeutics is a Boston-based preclinical neuroscience company developing non-hallucinatory, neuroplasticity-promoting therapeutics called psychoplastogens to treat mental illness and other brain disorders at scale. Its small-molecule compounds are designed to rapidly induce structural and functional neural changes in targeted brain regions while avoiding the hallucinogenic effects of first-generation psychedelics. Delix's discovery engine has produced nearly 1,000 novel compounds and identified several potential clinical development candidates. Its most advanced, orally bioavailable analogs—profiled in Nature and Cell—seek to preserve long-lasting beneficial neural rewiring without the safety liabilities and access barriers of classic psychedelics. The company raised $70M in a Series A to advance its non-hallucinatory, take-home candidates into clinical trials and to expand its team. DLX-1 and DLX-7, the first two development candidates, are undergoing pre-IND safety and toxicology studies to enable clinical trials in 2022.

Led · Seed · Sep 2021

The Alexander Shulgin Research Institute (ASRI) is a psychedelics discovery, development, and educational organization dedicated to continuing and extending the work of Dr. Alexander “Sasha” Shulgin. It focuses on design, chemical synthesis, and pharmacological evaluation of novel compounds as well as characterization of hundreds of compounds from the Shulgin Vault. ASRI has synthesized and supplied compounds for basic chemical, pharmacological, and clinical studies at universities and research organizations worldwide, and has supported recent FDA‑approved clinical research with psilocybin and DMT. The institute was informally founded by Dr. Shulgin in the 1980s and was formally incorporated on April 19, 2021; Paul F. Daley, Ph.D., and Nicholas V. Cozzi, Ph.D. lead the organization. The company emphasizes scientific excellence, high ethical standards, and education, and the Seed financing is intended to support establishment of a modern Shulgin Research Laboratory. The press release lists Toronto, ON as the release location.

Led · Series A · Sep 2021

CaaMTech is an Issaquah, WA–based psychedelic drug discovery company founded in 2017 and led by founder and CEO Dr. Andrew Chadeayne. The company focuses on engineering psychedelic drugs and has produced an extensive library of novel, analytically pure compounds. Those compounds are nearing advancement into human trials. CaaMTech intends to use newly raised funds to support its cross-disciplinary science program and expand its leadership team. The company plans to advance its foremost drug development candidates into human trials. As of September 2021, CaaMTech raised $22M in a Series A financing led by Noetic Fund.

Participated · Series A · May 2021

Gilgamesh Pharmaceuticals pursues discovery and development of improved neuropsychiatric drugs, using a platform that combines neural-circuit translational methods with AI and machine learning to optimize safety, efficacy and dosing. Its pipeline includes the ibogaine-analog GM-3009 (supported by a $14 million NIDA grant), the oral NMDAR antagonist GM-1020 (completed Phase 1 SAD/MAD and progressed into Phase 2), non-hallucinogenic neuroplasticity candidates now in IND-enabling stages, and projects targeting M1/M4 receptors. In August 2025 the company completed a strategic divestiture of clinical-stage candidate GM-2505 to AbbVie for up to $1.2 billion, and it has a separate AbbVie collaboration that included a $65 million upfront payment and up to $1.95 billion in option/ milestone payments plus royalties. The company assembled a leadership team with extensive CNS drug-development experience and intends to use recent financing to fund clinical and preclinical programs and continued discovery efforts. Gilgamesh was founded in 2019 by Jonathan Sporn and Andrew Kruegel.